Clincosm LogoSign in Get a demo

Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)

Sponsor
Organon and Co (Industry)
Overall Status
Completed
CT.gov ID
NCT00805584
Collaborator
(none)
311
Enrollment
1
Arm
1
Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this study was to test the effectiveness and side effects of desloratadine (Aerius) in patients with hayfever. Patients took desloratadine once a day for 15 days. At the end of therapy, they scored how severe their hayfever symptoms were and how they responded to therapy. Side effects were recorded.

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
311 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Multi-center, Open-label, Non-comparative Study of the Relief of Nasal Symptoms and Tolerability in Subjects With Seasonal Allergic Rhinitis (SAR) Treated With Aerius.
Study Start Date :
May 1, 2003
Actual Primary Completion Date :
Jun 1, 2003
Actual Study Completion Date :
Jun 1, 2003

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm 1

Drug: desloratadine
Aerius (desloratadine) tablets; 5mg orally once a day in the morning for 15 days
Other Names:
  • Aerius, Clarinex, SCH 34117, descarboethoxyloratadine

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Relief of allergy symptoms [Baseline and end of therapy]

    Secondary Outcome Measures

    1. Global therapeutic response [End of therapy]

    2. Adverse events [Baseline and end of therapy]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.

    • Subjects must be >=18 years of age, of either sex and any race.

    • Women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using or agree to use an acceptable method of birth control. Women who are not currently sexually active must agree and consent to use some sort of contraception should they become sexually active while participating in the study.

    • Subjects must be in general good health, i.e., they must be free of any clinically significant disease (other than SAR) that would interfere with study evaluations.

    • Subjects must understand and be able to adhere to the dosing and visit schedules, and agree to report concomitant medications and adverse events to the Investigator or designee.

    • Subjects must have at least a positive history, self-reported history of signs and symptoms is acceptable, of recurring seasonal allergic rhinitis

    • Subjects must be clinically symptomatic with SAR at Visit 2 (Baseline): the total (nasal + non-nasal) symptom score must be >=8 points with a nasal congestion score of

    =2, and the non-nasal symptom score must be >=2. Subjects may be rescheduled up two additional times for the qualifying visit if they do not meet the minimum symptom scores.

    • Women of childbearing potential must have be negative pregnancy history at Visit 1.
    Exclusion Criteria:

    • Women who are pregnant or nursing.

    • Subjects who have not observed the designated washout periods for any of the prohibited medications.

    • Subjects with asthma who require chronic use of inhaled or systemic corticosteroids.

    • Subjects with current or history of frequent, clinically significant sinusitis or chronic purulent postnasal drip.

    • Subjects with rhinitis medicamentosa.

    • Subjects who have had an upper respiratory tract or sinus infection that required antibiotic therapy within 14 days prior to Visit 1 (Screening / Consent), or subjects who have had a viral upper respiratory infection within 7 days prior to Visit 1.

    • Subjects who have nasal structural abnormalities, including nasal polyps and marked septal deviation, that significantly interferes with nasal airflow.

    • Subjects who, in the opinion of the Investigator, are dependent upon nasal, oral or ocular decongestants, nasal topical antihistamines, or nasal steroids.

    • Subjects with a history of hypersensitivity to desloratadine or any of its excipients.

    • Subjects who are staff personnel directly involved with the administration of this study.

    • Subjects who have any current evidence of clinically significant hematopoetic, metabolic, cardiovascular, immunologic, neurologic, hematologic, gastrointestinal, hepatic, renal, psychiatric, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the Investigator, may interfere with the study evaluations or affect subject safety.

    • Subject taking prohibited drugs listed in the study protocol are excluded from participation.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Organon and Co

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Organon and Co
    ClinicalTrials.gov Identifier:
    NCT00805584
    Other Study ID Numbers:
    • P03442
    First Posted:
    Dec 9, 2008
    Last Update Posted:
    Feb 17, 2022
    Last Verified:
    Feb 1, 2022
    Additional relevant MeSH terms:
    Rhinitis
    Rhinitis, Allergic
    Rhinitis, Allergic, Seasonal
    Desloratadine

    Study Results

    No Results Posted as of Feb 17, 2022